A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV) — Stella
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(13 sites)
United States
Stanford University, Dept. of Dermatology, Redwood City, California
UC Davis, Dept. of Dermatology, Sacramento, California
Yale University, New Haven, Connecticut
Northwestern University, Chicago, Illinois
University of Iowa, Iowa City, Iowa
Brigham and Women's Hospital, Boston, Massachusetts
Mount Sinai - Icahn School of Medicine, New York, New York
Columbia University, New York, New York
University of North Carolina, Department of Dermatology, Chapel Hill, North Carolina
University of Pennsylvania, Philadelphia, Pennsylvania
UT Southwestern Medical Center, Dept. of Dermatology, Dallas, Texas